March 25, 2020 / 12:20 PM / 12 days ago

BRIEF-Avadel Pharmaceuticals Completes The Rest-On Phase 3 Pivotal Trial Of FT218 For Excessive Daytime Sleepiness And Cataplexy In Patients With Narcolepsy

March 25 (Reuters) - Avadel Pharmaceuticals PLC:

* AVADEL PHARMACEUTICALS COMPLETES THE REST-ON PHASE 3 PIVOTAL TRIAL OF FT218 FOR EXCESSIVE DAYTIME SLEEPINESS AND CATAPLEXY IN PATIENTS WITH NARCOLEPSY

* AVADEL PHARMACEUTICALS PLC - CURRENTLY EXPECTS TO ANNOUNCE TOPLINE DATA FROM STUDY IN Q2 OF 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below